Contact
GBG Forschungs GmbH
Dornhofstraße 10
63263 Neu-Isenburg
Germany
Phone.: +49610274800
Fax: +4961027480440
E-Mail: Infgbgd
Contact form
News
18.11.2022 Desiree: dose escalation of everolimus published
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
Mehr ...08.11.2022 GBG research at SABCS 2022
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
Mehr ...14.10.2022 Location of Subcutaneous Trastuzumab Injection
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
Mehr ...30.09.2022 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
Mehr ...02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
Mehr ...